Top cited articles

Acceptance rate

37%

Time to first decision

21 days*

Time from acceptance to publication

18 days*

Impact Factor

5.117

Citescore

6.1

Citescore rank

14/56

Early experience of COVID-19 vaccination in adults with systemic rheumatic diseases: results from the COVID-19 Global Rheumatology Alliance Vaccine Survey
Sattui, Sebastian Eduardo; Liew, Jean W.; Kennedy, Kevin. et al
10.1136/rmdopen-2021-001814

Glucocorticoids in rheumatoid arthritis: current status and future studies
Hua, Charlotte; Buttgereit, Frank; Combe, Bernard
10.1136/rmdopen-2017-000536

Beneficial effects of colchicine for moderate to severe COVID-19: a randomised, double-blinded, placebo-controlled clinical trial
Lopes, Maria Isabel; Bonjorno, Leticia P.; Giannini, Marcela C. et al
10.1136/rmdopen-2020-001455

Reactive arthritis after COVID-19 infection
Ono, Keisuke; Kishimoto, Mitsumasa; Shimasaki, Teppei. et al
10.1136/rmdopen-2020-001350

High levels of immunosuppression are related to unfavourable outcomes in hospitalised patients with rheumatic diseases and COVID-19: first results of ReumaCoV Brasil registry
Lopes Marques, Claudia Diniz; Kakehasi, Adriana Maria. et al
10.1136/rmdopen-2020-001461

DMARD-free remission as novel treatment target in rheumatoid arthritis: A systematic literature review of achievability and sustainability
Verstappen, M.; van Mulligen, E.; de Jong, P. H. P. et al
10.1136/rmdopen-2020-001220

Assessment of impact of the COVID-19 pandemic from the perspective of patients with rheumatic and musculoskeletal diseases in Europe: results from the REUMAVID study (phase 1)
Garrido-Cumbrera, Marco; Marzo-Ortega, Helena; Christen, Laura. et al
10.1136/rmdopen-2020-001546

Prevalence and distribution of peripheral musculoskeletal manifestations in spondyloarthritis including psoriatic arthritis: results of the worldwide, cross-sectional ASAS-PerSpA study
Lopez-Medina, Clementina; Molto, Anna; Sieper, Joachim. et al
10.1136/rmdopen-2020-001450

Assessing the sensitivity to change of the OMERACT ultrasound structural gout lesions during urate-lowering therapy
Christiansen, Sara Nysom; Ostergaard, Mikkel; Slot, Ole. et al
10.1136/rmdopen-2019-001144

5-year follow-up of spinal and sacroiliac MRI abnormalities in early axial spondyloarthritis: data from the DESIR cohort
Madari, Queeny; Sepriano, Alexandre; Ramiro, Sofia. et al
10.1136/rmdopen-2019-001093

TNFi is associated with positive outcome, but JAKi and rituximab are associated with negative outcome of SARS-CoV-2 infection in patients with RMD
Regierer, Anne Constanze; Hasseli, Rebecca; Schaefer, Martin. et al
10.1136/rmdopen-2021-001896

Storm, typhoon, cyclone or hurricane in patients with COVID-19? Beware of the same storm that has a different origin
Alunno, Alessia; Carubbi, Francesco; Rodriguez-Carrio, Javier
10.1136/rmdopen-2020-001295

Point of view on the vaccination against COVID-19 in patients with autoimmune inflammatory rheumatic diseases
Furer, Victoria; Rondaan, Christien; Agmon-Levin, Nancy. et al
10.1136/rmdopen-2021-001594

Long-term safety of tofacitinib up to 9.5 years: a comprehensive integrated analysis of the rheumatoid arthritis clinical development programme
Cohen, Stanley B.; Tanaka, Yoshiya; Mariette, Xavier. et al
10.1136/rmdopen-2020-001395

Vaccination of patients with inflammatory rheumatic diseases against SARS-CoV-2: considerations before widespread availability of the vaccines
Schulze-Koops, Hendrik; Specker, Christof; Skapenko, Alla
10.1136/rmdopen-2020-001553

Impact of COVID-19 on vulnerable patients with rheumatic disease: results of a worldwide survey
Mehta, Bella; Jannat-Khah, Deanna; Fontana, Mark Alan. et al
10.1136/rmdopen-2020-001378

Antiphospholipid antibodies in COVID-19: a meta-analysis and systematic review
Taha, Muhanad; Samavati, Lobelia
10.1136/rmdopen-2021-001580

Management of Fatigue in Rheumatoid Arthritis
Pope, Janet E.
10.1136/rmdopen-2019-001084

Self-protection strategies and health behaviour in patients with inflammatory rheumatic diseases during the COVID-19 pandemic: results and predictors in more than 12 000 patients with inflammatory rheumatic diseases followed in the Danish DANBIO registry
Glintborg, Bente; Jensen, Dorte Vendelbo; Engel, Sara. et al
10.1136/rmdopen-2020-001505

Dual neutralisation of IL-17F and IL-17A with bimekizumab blocks inflammation-driven osteogenic differentiation of human periosteal cells
Shah, Mittal; Maroof, Asher; Gikas, Panos. et al
10.1136/rmdopen-2020-001306